Integrin αvβ5 has been identified as a regulator of vascular leak and endothelial permeability. We hypothesized that targeting αvβ5 could represent a viable treatment strategy for sepsis.
Integrin β5 subunit knockout and wild-type 129/svJae mice and wild-type mice treated with αvβ5 blocking or control antibodies were tested in models of intraperitoneal lipopolysaccharide and cecal ligation and puncture. Human umbilical vein endothelial cell and human lung microvascular endothelial cell monolayers were treated with αvβ5 antibodies to assess for effects on lipopolysaccharide-induced changes in transendothelial resistance and on patterns of cytoskeletal reorganization.
Mice and endothelial cell monolayers.
Measurements taken after intraperitoneal lipopolysaccharide and/or cecal ligation and puncture included mortality, vascular leak, hematocrit, quantification of a panel of serum cytokines/chemokines, and assessment of thioglyccolate-induced leukocyte migration. β5 knockout mice had decreased mortality after intraperitoneal lipopolysaccharide and cecal ligation and puncture and decreased vascular leak, as measured by extravasation of an I125-labeled intravascular tracer. Treating clinically ill mice with αvβ5 antibodies, up to 20 hrs after intraperitoneal lipopolysaccharide and cecal ligation and puncture, also resulted in decreased mortality. αvβ5 antibodies attenuated lipopolysaccharide-induced transendothelial resistance changes and cytoskeletal stress fiber formation in both human umbilical vein endothelial cell and human lung microvascular endothelial cell monolayers. αvβ5 antibodies had no effect on cytokine/chemokine serum levels after cecal ligation and puncture. β5 knockout mice and wild-type controls did not exhibit differences in thioglyccolate-induced leukocyte migration.
Our studies suggest that αvβ5 is an important regulator of the vascular endothelial leak response in sepsis and that αvβ5 blockade may provide a novel approach to treating this devastating disease syndrome.
Supplemental Digital Content is available in the text.
1 Lung Biology Center, University of California, San Francisco, CA.
2 Division of Pulmonary and Critical Care, and Cardiovascular Research Institute, University of California, San Francisco, CA.
*See also p. 686.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (http://journals.lww.com/ccmjournal).
Drs. Su and Sheppard contributed in conception and design, analysis and interpretation, and drafting the article for important intellectual content; Dr. Su, Mr. Atakilit, Dr. Li, Dr. Wu, Mr. Luong, and Mr. Chen helped in data acquisition.
This work was supported by NIH grants HL083950 and HL53949 (Dr. Sheppard) and 5K08HL83097-2 (Dr. Su).
Dr. Su, Mr. Atakilit, and Dr. Sheppard are co-owners of a patent describing treatment of sepsis and acute lung injury with an antibody against integrin αvβ5. The remaining authors have not disclosed any potential conflicts of interest.
For information regarding this article, E-mail: email@example.com